Drugs / Elafin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03522935 | Mar → Oct 2019 | pulmonary arterial hypertension | Roham T. Zamanian | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elafin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03522935 ↗ |
| Action | Inhibit | “Elafin inhibits elastase” NCT03522935 ↗ |
| Route | Subcutaneous | “Elafin will be administered subcutaneously daily for 7 days” NCT03522935 ↗ |